Shares of Minimally Invasive Brain Science (02172) surged more than 14% after the earnings report, and as of press time, the stock has risen 14.64%, to HKD 7.36, with a turnover of HKD 2.2779 million.
According to the Zhixin Finance app, shares of Minimally Invasive Brain Science (02172) surged more than 14% after the earnings report, with the stock rising 14.64% to HKD 7.36, and turnover hitting HKD 2.2779 million.
On the news front, Minimally Invasive Brain Science announced that it expects to generate revenue of approximately RMB 400 million to RMB 410 million for the six months ending June 30, 2024, representing a year-on-year increase of around 34% to 37%. The anticipated increase in revenue is mainly due to breakthrough progress in overseas business, with revenue expected to increase by approximately 70% to 90% on a year-on-year basis during the reporting period; and increased market share for products related to intracranial atherosclerotic stenosis (including Bridge vertebral artery sirolimus-targeted elution stent system, APOLLO intracranial arterial stent system, etc.), which achieved significant revenue growth.